Tilray Brands Inc. (TLRY) jumped 28% on Thursday, leading a broad rally in cannabis stocks after multiple reports indicated the Trump administration is preparing to reclassify marijuana from a Schedule I controlled substance under federal law. The move would mark the most significant shift in U.S. cannabis policy in decades, potentially unlocking legal interstate commerce and opening banking services for dispensaries.

Market Context

The cannabis rally rippled across the sector, with the AdvisorShares Pure Cannabis ETF (YOLO) rising 18% on the session. The S&P 500 slipped 0.3% in afternoon trading, creating a stark divergence between the cannabis sector and broader equities. The rally followed weeks of speculation surrounding the administration's stance on cannabis policy after campaign signals suggesting a potential softening of federal restrictions.

Analysis

The reported reclassification stems from an ongoing Department of Health and Human Services review, according to sources familiar with the matter. Institutional flow into cannabis names accelerated in early trading, with volume in Tilray reaching 45 million shares by mid-session—well above its 30-day average of 12 million. The shift from Schedule I to Schedule III or lower would remove significant regulatory barriers, potentially allowing major institutions to allocate capital to the sector for the first time. Analysts at Cantor Fitzgerald noted the policy change could unlock an estimated $30 billion in legal cannabis market value, though they cautioned that implementation timelines remain uncertain.

Key Numbers

- Tilray (TLRY): +28% on volume of 45 million shares

- Canopy Growth (CWE): +22%, volume 8.2 million shares

- Aurora Cannabis (ACB): +19%

- Cronos Group (CRON): +17%

- AdvisorShares Pure Cannabis ETF (YOLO): +18%

- 30-day average volume for TLRY: 12 million shares

What to Watch

Traders should monitor the DEA's formal scheduling decision, expected within 60 days according to policy sources. The rescheduling could face legal challenges from states with stricter marijuana prohibitions. Key levels to watch include TLRY resistance at $4.50 and support near $3.20. Earnings from major multi-state operators next month will provide insight into how companies are positioning for potential federal legalization. Institutional investors may begin building positions ahead of the formal ruling, though some portfolio managers remain cautious given the political uncertainty surrounding implementation.